NEW YORK – Quidel is massively ramping up production of its molecular diagnostic and antigen tests to meet skyrocketing demands for SARS-CoV-2 testing in the US.
In a call with investors on Thursday the firm outlined its manufacturing strategies and guided for an expected windfall third quarter. Quidel also provided details on Friday related to $71 million in National Institutes of Health funding to support planned expansions.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.